Six new medicines leap towards EU approval
The recommendations include new treatments for cancer and intraocular pressure and prevention of uncomplicated flu.
Read More
Tag: Samsung Bioepis
Biogen, Samsung Bioepis and Abbvie settle patent dispute
Biogen and Samsung Bioepis have laid to rest a long-running patent wrangle with AbbVie regarding a biosimilar form of the latter’s blockbuster Humira.
Read More
UK launch for Europe’s first Herceptin biosimilar
MSD has launched in the UK Europe’s first biosimilar to Roche/Genentech’s Herceptin, providing an alternative option for treating early breast cancer, metastatic breast cancer and metastatic gastric cancer.
Read More
Samsung Bioepis ventures into novel R&D with Takeda deal
Samsung Bioepis is joining forces with Takeda Pharmaceutical to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas, taking its first step towards developing new pharmaceuticals.
Read More
US green light for Remicade biosimilar
US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications.
Read More
EU regulators to review Herceptin biosimilar
European regulators have agreed to review Samsung Bioepis’ application to market SB3, a biosimilar of Roche’s cancer drug Herceptin.
Read More
EU to review Samsung Bioepis’ Humira biosimilar
European regulators have agreed to review Samsung Bioepis’ SB5, a biosimilar version of AbbVie’s Humira, the world’s second-best selling drug.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
